biohack.The longevity wire
LIVE WIREUpdated · scanning every 6 hours
05:35 One-time immune cell therapy held MS steady in early trial, maker says✦05:44 Lilly moves a Zepbound add-on that boosted weight loss into big trials✦05:43 Own tumor immune cells plus Keytruda made melanoma vanish on scans in 29%✦05:39 DNA of 8 long-lived bat species ties virus defenses to long life✦05:36 Cholesterol pills cut heart problems in healthy older people, not dementia✦05:32 One-time gene therapy for Duchenne muscle disease met its main trial goal✦05:40 Adding a second immune drug cut death risk 58% in deadly lung cancer trial✦05:27 Custom-made melanoma vaccine cut risk of return or death 42% in big trial✦05:35 One-time immune cell therapy held MS steady in early trial, maker says✦05:44 Lilly moves a Zepbound add-on that boosted weight loss into big trials✦05:43 Own tumor immune cells plus Keytruda made melanoma vanish on scans in 29%✦05:39 DNA of 8 long-lived bat species ties virus defenses to long life✦05:36 Cholesterol pills cut heart problems in healthy older people, not dementia✦05:32 One-time gene therapy for Duchenne muscle disease met its main trial goal✦05:40 Adding a second immune drug cut death risk 58% in deadly lung cancer trial✦05:27 Custom-made melanoma vaccine cut risk of return or death 42% in big trial
← All story threadsSTORY THREAD

Lilly's two-drug weight-loss shot built on Zepbound.

1 report so far. New developments are added to this thread as they happen.

  1. Oct 25, 2026
    TWO LARGE FINAL-STAGE TRIALS REGISTEREDCompany results · 367 adults

    Lilly moves a Zepbound add-on that boosted weight loss into big trials

    Eli Lilly has registered two large trials of a shot that pairs the drug in Zepbound with a fullness-hormone drug. The open question is how many people can stay on it.